22nd Century (XXII)
NASDAQ:XXII
Want to see XXII full AI Analyst Report?
XXII Stock Chart & Stats
$0.76
-$0.08(-1.39%)
At close: 4:00 PM EST
$0.76
-$0.08(-1.39%)
Day’s Range― - ―
52-Week Range$0.36 - $253.89
Previous CloseN/A
Volume40.32K
Average Volume (3M)2.49M
Market Cap
$1.63M
Enterprise Value-$8.61M
Total Cash (Recent Filing)$9.54M
Total Debt (Recent Filing)$841.00K
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-214.80
Shares Outstanding4,455,649
10 Day Avg. Volume328,967
30 Day Avg. Volume2,485,312
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.30
P/FCF Ratio-0.25
Enterprise Value/Market Cap-5.30
Enterprise Value/Revenue-0.97
Enterprise Value/Gross Profit2.65
Enterprise Value/Ebitda0.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$32.50M
Bulls Say, Bears Say
Bulls Say
Strengthened Balance Sheet And LiquidityHaving $9.5M cash and management focus on disciplined allocation materially increases runway and optionality over the next 2–6 months. A stronger liquidity position reduces short-term financing pressure and supports funded investment in distribution and marketing to scale commercial traction.
Regulatory Differentiation (FDA Authorization)Possessing the only FDA-authorized very low nicotine (VLN) cigarette creates a durable regulatory moat, easing market access and lending credibility with retailers and public health dialogues. This structural regulatory endorsement supports licensing, partnerships, and longer-term product positioning.
Early Distribution Wins And Retail Scaling PlanAgreements with large purveyors and a clear outlet growth target (~5,000 stores) underpin a scalable commercial pathway. Durable benefits include expanded shelf presence, stronger bargaining with suppliers, and the potential for network effects as retailer adoption and merchandising investments compound over months.
Bears Say
Negative Gross Profit And Ongoing Operating LossesSustained negative gross profit means the core product economics are not yet viable; operating losses compound this structural problem. Over 2–6 months, absent material margin improvement or higher-margin mix, persistent losses will limit self-funding and constrain reinvestment into growth initiatives.
Continued Cash Burn And Negative Operating Cash FlowA roughly $7.9M annualized cash outflow indicates the business is consuming cash faster than it generates it. This structural cash burn necessitates external funding or asset sales, increasing execution risk and diverting management attention from commercial scaling to capital raises.
Reliance On Dilutive Financing And Potential Shareholder DilutionMaterial recent financings (Series B preferred, warrant coverage and an available ATM program) show reliance on external capital. Over the medium term this can dilute common equity, constrain upside for existing shareholders, and shift priority toward preserving liquidity rather than accelerating margin improvements.
22nd Century News
XXII FAQ
What was 22nd Century’s price range in the past 12 months?
22nd Century lowest stock price was $0.35 and its highest was $253.89 in the past 12 months.
What is 22nd Century’s market cap?
22nd Century’s market cap is $1.63M.
When is 22nd Century’s upcoming earnings report date?
22nd Century’s upcoming earnings report date is Aug 19, 2026 which is in 70 days.
How were 22nd Century’s earnings last quarter?
22nd Century released its earnings results on May 07, 2026. The company reported -$5.07 earnings per share for the quarter, missing the consensus estimate of N/A by -$5.07.
Is 22nd Century overvalued?
According to Wall Street analysts 22nd Century’s price is currently Overvalued.
Does 22nd Century pay dividends?
22nd Century does not currently pay dividends.
What is 22nd Century’s EPS estimate?
22nd Century’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 22nd Century have?
22nd Century has 4,455,649 shares outstanding.
What happened to 22nd Century’s price movement after its last earnings report?
22nd Century reported an EPS of -$5.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -16.353%.
Which hedge fund is a major shareholder of 22nd Century?
Currently, no hedge funds are holding shares in XXII
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
22nd Century
22nd Century Group, Inc. is an agricultural biotechnology firm dedicated to mitigating the risks associated with tobacco use and improving health and wellness through advanced plant science. The company serves the life science and consumer product sectors. Its innovations include ultra-low nicotine tobacco and cigarette offerings, marketed under the VLN King and VLN Menthol King brands, as well as SPECTRUM research cigarettes used in independent scientific investigations. Furthermore, 22nd Century Group collaborates with Keygene N.V. to cultivate hemp and cannabis plants engineered for superior cannabinoid content and enhanced agricultural characteristics, intended for medical, therapeutic, farming, and other applications. Established in 1998, the company is based in Buffalo, New York.
XXII Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed cautious optimism: management reported clear early commercial progress with sequential revenue growth, gross loss improvement, strategic retail distribution wins, regulatory validation (FDA authorization) and a stable cash position. However, material challenges remain — operating losses and negative adjusted EBITDA widened, profitability is below targets, low-margin contracts persist, and retail adoption is uneven. Management plans focused investments in marketing and distribution with a target of ~5,000 outlets by year-end, but execution risk and competitive headwinds mean near-term results may continue to be pressured.View all XXII earnings summariesTechnical Analysis
Universal
―
Turning Point Brands
―
Greenlane Holdings
―
Kaival Brands Innovations Group
―
Ispire Technology, Inc.
―
Ownership Overview
5.68% Insiders
0.10% Mutual Funds
1.14% Other Institutional Investors
93.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---